{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:48:05Z","timestamp":1792504085607,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Key messages<\/jats:title>\n                    <jats:p>In this study including 391 critically ill patients with nosocomial pneumonia due to Gram-negative pathogens, combination therapy was not associated with a reduced hazard of death at Day 28 or a greater likelihood of clinical cure at Day 14. No over-risk of AKI was observed in patients receiving combination therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The benefits and harms of combination antimicrobial therapy remain controversial in critically ill patients with hospital-acquired pneumonia (HAP), ventilated HAP (vHAP) or ventilator-associated pneumonia (VAP) involving Gram-negative bacteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included all patients in the prospective multicenter OutcomeRea database with a first HAP, vHAP or VAP due to a single Gram-negative bacterium and treated with initial adequate single-drug or combination therapy. The primary endpoint was Day-28 all-cause mortality. Secondary endpoints were clinical cure rate at Day 14 and a composite outcome of death or treatment-emergent acute kidney injury (AKI) at Day 7. The average effects of combination therapy on the study endpoints were investigated through inverse probability of treatment-weighted regression and multivariable regression models. Subgroups analyses were performed according to the resistance phenotype of the causative pathogens (multidrug-resistant or not), the pivotal (carbapenems or others) and companion (aminoglycosides\/polymyxins or others) drug classes, the duration of combination therapy (&lt;\u20093 or\u2009\u2265\u20093\u00a0days), the SOFA score value at pneumonia onset (&lt;\u20097 or\u2009\u2265\u20097 points), and in patients with pneumonia due to non-fermenting Gram-negative bacteria, pneumonia-related bloodstream infection, or septic shock.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 391 included patients, 151 (38.6%) received single-drug therapy and 240 (61.4%) received combination therapy. VAP (overall, 67.3%), vHAP (16.4%) and HAP (16.4%) were equally distributed in the two groups. All-cause mortality rates at Day 28 (overall, 31.2%), clinical cure rate at Day 14 (43.7%) and the rate of death or AKI at Day 7 (41.2%) did not significantly differ between the groups. In inverse probability of treatment-weighted analyses, combination therapy was not independently associated with the likelihood of all-cause death at Day 28 (adjusted odd ratio [aOR], 1.14; 95% confidence interval [CI] 0.73\u20131.77;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.56), clinical cure at Day 14 (aOR, 0.79; 95% CI 0.53\u20131.20;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.27) or death or AKI at Day 7 (aOR, 1.07; 95% CI 0.71\u20131.63;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.73). Multivariable regression models and subgroup analyses provided similar results.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Initial combination therapy exerts no independent impact on Day-28 mortality, clinical cure rate at Day 14, and the hazard of death or AKI at Day 7 in critically ill patients with mono-bacterial HAP, vHAP or VAP due to Gram-negative bacteria.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13054-023-04792-0","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T14:03:03Z","timestamp":1704290583000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Single-drug versus combination antimicrobial therapy in critically ill patients with hospital-acquired pneumonia and ventilator-associated pneumonia due to Gram-negative pathogens: a multicenter retrospective cohort study"],"prefix":"10.1186","volume":"28","author":[{"given":"Fran\u00e7ois","family":"Barbier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Dupuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Buetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Schwebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9lie","family":"Azoulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Argaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien","family":"Hong Tuan Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Gainnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shidasp","family":"Siami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Forel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Adrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9tienne","family":"de Montmollin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Reignier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Ruckly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Ralph","family":"Zahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Timsit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the OutcomeR\u00e9a Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"issue":"8","key":"4792_CR1","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1097\/CCM.0000000000003225","volume":"46","author":"CM Coopersmith","year":"2018","unstructured":"Coopersmith CM, De Backer D, Deutschman CS, Ferrer R, Lat I, Machado FR, et al. Surviving Sepsis Campaign: research priorities for sepsis and septic shock. Crit Care Med. 2018;46(8):1334\u201356.","journal-title":"Crit Care Med"},{"issue":"2","key":"4792_CR2","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s00134-019-05520-5","volume":"45","author":"JF Timsit","year":"2019","unstructured":"Timsit JF, Bassetti M, Cremer O, Daikos G, de Waele J, Kallil A, et al. Rationalizing antimicrobial therapy in the ICU: a narrative review. Intensive Care Med. 2019;45(2):172\u201389.","journal-title":"Intensive Care Med"},{"issue":"4","key":"4792_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jinf.2016.11.013","volume":"74","author":"F Sj\u00f6vall","year":"2017","unstructured":"Sj\u00f6vall F, Perner A, Hylander MM. Empirical mono- versus combination antibiotic therapy in adult intensive care patients with severe sepsis\u2014a systematic review with meta-analysis and trial sequential analysis. J Infect. 2017;74(4):331\u201344.","journal-title":"J Infect"},{"issue":"3","key":"4792_CR4","doi-asserted-by":"publisher","first-page":"1700582","DOI":"10.1183\/13993003.00582-2017","volume":"50","author":"A Torres","year":"2017","unstructured":"Torres A, Niederman MS, Chastre J, Ewig S, Fernandez-Vandellos P, Hanberger H, et al. International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)\/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociaci\u00f3n Latinoamericana del T\u00f3rax (ALAT). Eur Respir J. 2017;50(3):1700582.","journal-title":"Eur Respir J"},{"issue":"5","key":"4792_CR5","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61-111.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4792_CR6","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1128\/CMR.05041-11","volume":"25","author":"PD Tamma","year":"2012","unstructured":"Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with Gram-negative bacteria. Clin Microbiol Rev. 2012;25(3):450\u201370.","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"4792_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/01.CCM.0000297956.27474.9D","volume":"36","author":"MAW Aarts","year":"2008","unstructured":"Aarts MAW, Hancock JN, Heyland D, McLeod RS, Marshall JC. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit Care Med. 2008;36(1):108\u201317.","journal-title":"Crit Care Med"},{"issue":"3","key":"4792_CR8","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/01.CCM.0B013E31816203D6","volume":"36","author":"DK Heyland","year":"2008","unstructured":"Heyland DK, Dodek P, Muscedere J, Day A, Cook D, Canadian Critical Care Trials Group. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med. 2008;36(3):737\u201344.","journal-title":"Crit Care Med"},{"issue":"2","key":"4792_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1086\/430912","volume":"41","author":"IA Bliziotis","year":"2005","unstructured":"Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis. 2005;41(2):149\u201358.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"4792_CR10","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1097\/01.CCM.0000275389.31974.22","volume":"35","author":"J Garnacho-Montero","year":"2007","unstructured":"Garnacho-Montero J, Sa-Borges M, Sole-Violan J, Barcenilla F, Escoresca-Ortega A, Ochoa M, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med. 2007;35(8):1888\u201395.","journal-title":"Crit Care Med"},{"issue":"5","key":"4792_CR11","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1080\/23744235.2016.1277035","volume":"49","author":"L Deconinck","year":"2017","unstructured":"Deconinck L, Meybeck A, Patoz P, Van Grunderbeeck N, Boussekey N, Chiche A, et al. Impact of combination therapy and early de-escalation on outcome of ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Infect Dis Lond Engl. 2017;49(5):396\u2013404.","journal-title":"Infect Dis Lond Engl"},{"issue":"1","key":"4792_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13054-023-04457-y","volume":"27","author":"A Foucrier","year":"2023","unstructured":"Foucrier A, Dessalle T, Tuffet S, Federici L, Dahyot-Fizelier C, Barbier F, et al. Association between combination antibiotic therapy as opposed as monotherapy and outcomes of ICU patients with Pseudomonas aeruginosa ventilator-associated pneumonia: an ancillary study of the iDIAPASON trial. Crit Care. 2023;27(1):211.","journal-title":"Crit Care"},{"issue":"12","key":"4792_CR13","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/cid\/cix186","volume":"64","author":"DSY Ong","year":"2017","unstructured":"Ong DSY, Frencken JF, Klein Klouwenberg PMC, Juffermans N, van der Poll T, Bonten MJM, et al. Short-course adjunctive gentamicin as empirical therapy in patients with severe sepsis and septic shock: a prospective observational cohort study. Clin Infect Dis. 2017;64(12):1731\u20136.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4792_CR14","first-page":"CD003344","volume":"2014","author":"M Paul","year":"2014","unstructured":"Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev. 2014;2014(1):CD003344.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"4792_CR15","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1097\/CCM.0b013e3181e96b91","volume":"38","author":"A Kumar","year":"2010","unstructured":"Kumar A, Safdar N, Kethireddy S, Chateau D. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic\/meta-regression study. Crit Care Med. 2010;38(8):1651\u201364.","journal-title":"Crit Care Med"},{"issue":"12","key":"4792_CR16","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1093\/jac\/dkx315","volume":"72","author":"M Ripa","year":"2017","unstructured":"Ripa M, Rodr\u00edguez-N\u00fa\u00f1ez O, Cardozo C, Naharro-Abell\u00e1n A, Almela M, Marco F, et al. Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: a propensity score-adjusted and matched analysis. J Antimicrob Chemother. 2017;72(12):3443\u201352.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"4792_CR17","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/1471-2334-12-308","volume":"16","author":"SY Park","year":"2012","unstructured":"Park SY, Park HJ, Moon SM, Park KH, Chong YP, Kim MN, et al. Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia. BMC Infect Dis. 2012;16(12):308.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"4792_CR18","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1093\/jac\/dkv423","volume":"71","author":"F Barbier","year":"2016","unstructured":"Barbier F, Pommier C, Essaied W, Garrouste-Orgeas M, Schwebel C, Ruckly S, et al. Colonization and infection with extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure? J Antimicrob Chemother. 2016;71(4):1088\u201397.","journal-title":"J Antimicrob Chemother"},{"issue":"9596","key":"4792_CR19","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453\u20137.","journal-title":"Lancet"},{"issue":"157","key":"4792_CR20","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0023-2020","volume":"29","author":"MS Vallecoccia","year":"2020","unstructured":"Vallecoccia MS, Domined\u00f2 C, Cutuli SL, Martin-Loeches I, Torres A, De Pascale G. Is ventilated hospital-acquired pneumonia a worse entity than ventilator-associated pneumonia? Eur Respir Rev. 2020;29(157): 200023.","journal-title":"Eur Respir Rev"},{"issue":"2","key":"4792_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00134-019-05866-w","volume":"46","author":"A Tabah","year":"2020","unstructured":"Tabah A, Bassetti M, Kollef MH, Zahar JR, Paiva JA, Timsit JF, et al. Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP). Intensive Care Med. 2020;46(2):245\u201365.","journal-title":"Intensive Care Med"},{"issue":"3","key":"4792_CR22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268\u201381.","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"4792_CR23","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801\u201310.","journal-title":"JAMA"},{"issue":"11","key":"4792_CR24","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1093\/cid\/ciz093","volume":"69","author":"E Weiss","year":"2019","unstructured":"Weiss E, Zahar JR, Alder J, Asehnoune K, Bassetti M, Bonten MJM, et al. Elaboration of consensus clinical endpoints to evaluate antimicrobial treatment efficacy in future hospital-acquired\/ventilator-associated bacterial pneumonia clinical trials. Clin Infect Dis. 2019;69(11):1912\u20138.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"4792_CR25","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179-184.","journal-title":"Nephron Clin Pract"},{"issue":"1","key":"4792_CR26","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s13054-023-04641-0","volume":"27","author":"CY See","year":"2023","unstructured":"See CY, Pan HC, Chen JY, Wu CY, Liao HW, Huang YT, et al. Improvement of composite kidney outcomes by AKI care bundles: a systematic review and meta-analysis. Crit Care Lond Engl. 2023;27(1):390.","journal-title":"Crit Care Lond Engl"},{"issue":"28","key":"4792_CR27","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661\u201379.","journal-title":"Stat Med"},{"issue":"22","key":"4792_CR28","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1001\/jama.2012.5833","volume":"307","author":"FM Brunkhorst","year":"2012","unstructured":"Brunkhorst FM, Oppert M, Marx G, Bloos F, Ludewig K, Putensen C, et al. Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA. 2012;307(22):2390\u20139.","journal-title":"JAMA"},{"issue":"1","key":"4792_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jcrc.2007.08.007","volume":"23","author":"EL Kuti","year":"2008","unstructured":"Kuti EL, Patel AA, Coleman CI. Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis. J Crit Care. 2008;23(1):91\u2013100.","journal-title":"J Crit Care"},{"issue":"7","key":"4792_CR30","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1089\/sur.2020.306","volume":"22","author":"B Jovanovic","year":"2021","unstructured":"Jovanovic B, Djuric O, Hadzibegovic A, Jovanovic S, Stanisavljevic J, Milenkovic M, et al. Trauma and antimicrobial resistance are independent predictors of inadequate empirical antimicrobial treatment of ventilator-associated pneumonia in critically ill patients. Surg Infect. 2021;22(7):730\u20137.","journal-title":"Surg Infect"},{"issue":"7","key":"4792_CR31","doi-asserted-by":"publisher","first-page":"e1601","DOI":"10.1093\/cid\/ciaa1441","volume":"73","author":"A Roquilly","year":"2021","unstructured":"Roquilly A, Chanques G, Lasocki S, Foucrier A, Fermier B, De Courson H, et al. Implementation of French recommendations for the prevention and the treatment of hospital-acquired pneumonia: a cluster-randomized trial. Clin Infect Dis. 2021;73(7):e1601\u201310.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4792_CR32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/CCM.0000000000003553","volume":"47","author":"W Ibn Saied","year":"2019","unstructured":"Ibn Saied W, Mourvillier B, Cohen Y, Ruckly S, Reignier J, Marcotte G, et al. A comparison of the mortality risk associated with ventilator-acquired bacterial pneumonia and nonventilator ICU-acquired bacterial pneumonia. Crit Care Med. 2019;47(3):345\u201352.","journal-title":"Crit Care Med"},{"issue":"10","key":"4792_CR33","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/infdis\/jiy578","volume":"219","author":"GH Talbot","year":"2019","unstructured":"Talbot GH, Das A, Cush S, Dane A, Wible M, Echols R, et al. Evidence-based study design for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. J Infect Dis. 2019;219(10):1536\u201344.","journal-title":"J Infect Dis"},{"issue":"12","key":"4792_CR34","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1164\/rccm.201001-0094OC","volume":"182","author":"M Esperatti","year":"2010","unstructured":"Esperatti M, Ferrer M, Theessen A, Liapikou A, Valencia M, Saucedo LM, et al. Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients. Am J Respir Crit Care Med. 2010;182(12):1533\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"4792_CR35","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","volume":"17","author":"B Guti\u00e9rrez-Guti\u00e9rrez","year":"2017","unstructured":"Guti\u00e9rrez-Guti\u00e9rrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Pa\u00f1o-Pardo JR, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17(7):726\u201334.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"4792_CR36","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/MD.0b013e318239cf0a","volume":"90","author":"ST Micek","year":"2011","unstructured":"Micek ST, Reichley RM, Kollef MH. Health care-associated pneumonia (HCAP): empiric antibiotics targeting methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa predict optimal outcome. Medicine (Baltimore). 2011;90(6):390\u20135.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"4792_CR37","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1473-3099(10)70314-5","volume":"11","author":"DH Kett","year":"2011","unstructured":"Kett DH, Cano E, Quartin AA, Mangino JE, Zervos MJ, Peyrani P, et al. Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis. 2011;11(3):181\u20139.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"4792_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1164\/rccm.201210-1897OC","volume":"188","author":"B Planquette","year":"2013","unstructured":"Planquette B, Timsit JF, Misset BY, Schwebel C, Azoulay E, Adrie C, et al. Pseudomonas aeruginosa ventilator-associated pneumonia predictive factors of treatment failure. Am J Respir Crit Care Med. 2013;188(1):69\u201376.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"4792_CR39","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S0002-9343(02)01476-6","volume":"114","author":"C Bartal","year":"2003","unstructured":"Bartal C, Danon A, Schlaeffer F, Reisenberg K, Alkan M, Smoliakov R, et al. Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med. 2003;114(3):194\u20138.","journal-title":"Am J Med"},{"issue":"2","key":"4792_CR40","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ijantimicag.2011.03.022","volume":"38","author":"R G\u00e1lvez","year":"2011","unstructured":"G\u00e1lvez R, Luengo C, Cornejo R, Kosche J, Romero C, Tobar E, et al. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Int J Antimicrob Agents. 2011;38(2):146\u201351.","journal-title":"Int J Antimicrob Agents"},{"key":"4792_CR41","doi-asserted-by":"crossref","unstructured":"The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med. 1993;119(7 Pt 1):584\u201393.","DOI":"10.7326\/0003-4819-119-7_Part_1-199310010-00006"},{"issue":"8","key":"4792_CR42","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.cmi.2019.04.013","volume":"25","author":"E Durante-Mangoni","year":"2019","unstructured":"Durante-Mangoni E, Andini R, Zampino R. Management of carbapenem-resistant Enterobacteriaceae infections. Clin Microbiol Infect. 2019;25(8):943\u201350.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"4792_CR43","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13613-023-01153-6","volume":"13","author":"F Barbier","year":"2023","unstructured":"Barbier F, Hraiech S, Kern\u00e9is S, Veluppillai N, Pajot O, Poissy J, et al. Rationale and evidence for the use of new beta-lactam\/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients. Ann Intensive Care. 2023;13(1):65.","journal-title":"Ann Intensive Care"},{"issue":"2","key":"4792_CR44","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00134-020-05929-3","volume":"46","author":"N Arulkumaran","year":"2020","unstructured":"Arulkumaran N, Routledge M, Schlebusch S, Lipman J, Conway MA. Antimicrobial-associated harm in critical care: a narrative review. Intensive Care Med. 2020;46(2):225\u201335.","journal-title":"Intensive Care Med"},{"issue":"4","key":"4792_CR45","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.2899","volume":"3","author":"C Rhee","year":"2020","unstructured":"Rhee C, Kadri SS, Dekker JP, Danner RL, Chen HC, Fram D, et al. Prevalence of antibiotic-resistant pathogens in culture-proven sepsis and outcomes associated with inadequate and broad-spectrum empiric antibiotic use. JAMA Netw Open. 2020;3(4): e202899.","journal-title":"JAMA Netw Open"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-023-04792-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-023-04792-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-023-04792-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:05:06Z","timestamp":1704326706000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-023-04792-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4792"],"URL":"https:\/\/doi.org\/10.1186\/s13054-023-04792-0","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,3]]},"assertion":[{"value":"27 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The OutcomeR\u00e9a database protocol was submitted to the Institutional Review Board of the Clermont-Ferrand University Hospital (Clermont-Ferrand, France) who waived the need for informed consent (IRB No. 5891).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"F. B. declares having received lecture and consulting fees from MSD, lecture fees for BioM\u00e9rieux and conference invitation from Pfizer, not related to the submitted work. J.-F. T. declares having received consulting fees from Gilead, MSD, Pfizer, BioM\u00e9rieux and Roche diagnostic, and lecture fees from MSD, Pfizer, Shionogi, BioM\u00e9rieux, Qiagen, Mundipharma and Gilead, not related to the submitted work. J.-R. Z. declares having received consulting fees and conference invitation from MSD, consulting fees, lecture fees and conference invitations from Pfizer, lecture Fees from Advanz-Pharma and Shionogui, and conference invitations from Biom\u00e9rieux and Gilead, not related to the submitted work. E. A. is Associate Editor of <i>Critical Care<\/i>. Other authors declare having no potential conflict of interest related to the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}